Opus Genetics, Inc.IRD

Opus Genetics, a clinical-stage gene-therapy outfit tucked inside North Carolina’s Research Triangle, filed its latest 10-Q on March 31 and quietly disclosed $2.2 million in revenue, a $65.5 million net loss, and 86.9 million diluted shares floating around. The company’s cash hoard stands at $60 million while liabilities have swollen to $87.9 million, leaving shareholders staring at a shareholders’ deficit of $45.8 million. In plain words, Opus is spending more than it earns and owing more than it owns, all while promising to cure blindness in young children with a single shot.

The polished story is simple: five gene therapies in the pipeline, a recent FDA thumbs-up for a Phase 3 design on OPGx-LCA5, and a BEST1 cohort read-out scheduled for the second week of September. The reality is less tidy. The FDA’s alignment on OPGx-LCA5 is a genuine step-Type B Rare Disease Exemption meetings do not happen by accident-but it is only permission to run a trial, not a guarantee of approval or revenue. The BEST1 program update promises “topline data in the second week of September,” which in drug-development parlance means the source directs readers to expect a press release, not a licence to print money. (source: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results, https://ir.opusgtx.com/press-releases/detail/538/opus-genetics-provides-best1-program-update-with-detailed-timeline-for-opgx-best1-results)

Behind the scenes, Opus relies on external manufacturers for bulk drug substance and third-party sites for clinical work, which the company flags as material risk in its latest 424B2 filing. Translation: if the contract manufacturer stumbles or the trial site stalls, the entire vision-restoration narrative runs into the backhoe. The same filing admits the future commercial success “could significantly depend” on reimbursement policies and the presence of rival products-factors entirely outside Opus’s control. On June 16 the company disclosed five gene-therapy programs targeting significant unmet need, yet the 10-Q shows no revenue line large enough to matter. Cash used in operations clocked in at $12.7 million for the quarter, leaving roughly five quarters of runway at current burn. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1228627/000197415826000090/xsl144X01/primary_doc.xml)

The company’s June 17 prospectus (424B2) sold $65 million of new shares at $7.50 apiece, pushing diluted share count to 86.9 million and earnings-per-share to a polite $0.75 loss. The filing also reminds readers that the company has no products on the market and no guarantee of reimbursement, manufacturing, or regulatory approval. In other words, the money raised is earmarked for the lab, not for dividends. (source: 424B2 (2026-06-17), https://www.sec.gov/Archives/edgar/data/1228627/000114036126025525/ny20075388x2_424b2.htm)

Opus Genetics trades on the OTCQB under the ticker IRD, but the real action is in the filings. For context, the stock has no formal chart path in the FreedomCore rails, so investors are left to parse the SEC documents rather than watch candlesticks. The next substantive inflection is the BEST1 cohort-one data drop, expected in the second week of September; anything less than a clean safety and efficacy signal will amplify the cash-burn narrative and could force another capital raise. Until then, the story remains a race between the balance sheet and the bioreactor. (source: SEC filings index, https://www.sec.gov/edgar/browse/?CIK=1228627)